Unapproved Prescription Cough, Cold, and Allergy Medications

To the Editor:
In a recent issue of CHEST (August 2011), Irwin and Smith 1 wrote an editorial on a commentary about the recent US Food and Drug Administration (FDA) enforcement action 2 on marketed unapproved prescription cough, cold, and allergy medications. 3 We appreciate the opportunity to provide insight into our action, which affects the American College of Chest Physicians cough guidelines. 4 We also thank Irwin and Smith for their support of our action.
Irwin and Smith 1 suggested that extended-release products compounded by state-licensed compounding pharmacies represent an additional option to address the lack of extended-release, fi rstgeneration antihistamines and extended-release, fi rst-generation antihistamine/pseudoephedrine combination products. They recommended that such products be compounded to meet United States Pharmacopeia-National Formulary standards. 5 We would like to point out that the United States PharmacopeiaNational Formulary 5 does not contain any standard or specification for any compounded extended-release drug product and, therefore, cannot by itself be a reference for the compounding of extended-release cough, cold, and allergy drug products. A compounding pharmacy would need to develop a drug formulation that had appropriate potency, purity, and performance characteristics to consistently yield a safe and effective product. Here, the compounding pharmacy would be faced with the same challenges, but with fewer resources, as drug manufacturers have in developing and testing an extended-release drug product that could be relied upon by physicians and patients, while avoiding problems with safety, effi cacy, dose dumping, and product-to-product variability. These are the same concerns that the FDA has with other unapproved compounded or manufactured extended-release drugs. For these reasons, the FDA recommends that practitioners not attempt to have pharmacists compound versions of the cough, cold, and allergy drug products as substitutes for those that were subject to the recent enforcement action of the FDA. Although the authors stress that it is important for clinicians to have an open dialogue with the compounding pharmacy regarding appropriate quality-control testing of compounded products, we have concerns that this option may not be a practical solution to the lack of availability of such products and recommend that practitioners instead rely on products of proven effi cacy and safety, as recommended in Ostroff et al. 3 Charles E. Lee 
